The Latest Breaking News from HIV

This biotech giant has hidden strengths that could unlock long-term upside.

The pioneering African country is lauded for slashing rates of mother-to-child transmission to just 1.2% and is holding trials that may now hold the key to curing young people

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

The UK has just introduced the world’s first national programme offering a vaccine to help protect against gonorrhoea. This coincides with increasing rates of sexually transmitted infections (STIs) including antibiotic-resistant strains of Neisseria gonorrhoeae, particularly among gay, bisexual and other men who have sex with men.

Eight months into Donald Trump’s second presidency of the United States, truth and science are again under attack – with global consequences. USAID, which tackled HIV, TB, malaria and child malnutrition is gone. Funding has been withdrawn from GAVI, a public–private global alliance that helps buy vaccines for the world’s…

A Hospice UK report released in 2023 found that end of life care received by trans and gender diverse people was usually not inclusive

Several vaccines for HIV have been tested in animal studies and an early safety trial in people, showing promising results in both.

Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization

Decisions from the U.S. Preventative Services Task Force impact millions of people’s access to preventative care for cancer, infectious diseases and mental health

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV